*Sponsored by Sica Media

The opportunity right now is too big for you to ignore, so make sure you pull up INDP on your screen right now and dig into it.


I’ll start by sharing some of my thoughts on it…


This small-cap, NYC-based biotech company has been ripping higher this year. As of the close Friday, it’s up a whopping 62% year-to-date and has tested highs of as much as 164% as recently as September.


This is remarkable among early-stage biotech companies, which often see steady declines buoyed only by great news.


This speaks to the strong standing of INDP and investors’ confidence in its potentially breakthrough therapeutics. More on that later, but first, let me tell you why this stock has caught my attention right now.


Headline describing technical reasons we see a breakout in INDP


Apart from a few minor upswings, INDP has dipped from its September highs.


But that all changed last week. On Monday, the stock opened at $2.05, but by the close Friday, it had reached $2.50 — an incredible move more than 20% higher in just 5 days.


For comparison, the SPY had one of its best moves in ages, and it “only” gained a little more than 5% on the week.


These are the types of outsized moves I’m looking for.


The question is: Will INDP’s run continue?


We can’t know for sure, of course, but we can take a very educated guess. 


Judging from what I see right now, I think last week’s 20% gain could just be the tip of the iceberg.


Normally, I would think this type of move in one week would be the “top” for a stock, but as I look at multiple timeframes, I am seeing lots of “GO” indicators from the algorithms I follow.


When I see good news for a small stock along with these types of technical indicators, I start to get on high alert.  


All of this bodes very well, but you should still look at what’s powered INDP’s explosive growth not only this week, but also over the past year.


Great News About the Company’s Lead Candidate


The big impetus for INDP’s 2023 rise appears to be the start of a Phase 1 clinical trial for its lead candidate, Decoy20, in December 2022, and the first patient dosing in March 2023.


The company had been sitting on dozens of issued or granted patents based on tech developed by Indaptus founder and chief scientific officer, Dr. Michael Newman, at Indaptus’ predecessor company, Decoy Biosystems.


The rubber finally met the road in 2023, though, and investors are clearly liking what they’re seeing.


I looked into Decoy20 and found it unusually interesting, and it’s easy to see why investors see such promise in it.


Decoy20 was inspired by the observation that tumors sometimes regress in the presence of a bacterial infection. The theory is that the infection may activate the immune system in a way the cancer doesn’t.


But you obviously don’t want to infect cancer patients with bacteria that could cause them sustained sickness.


Enter Decoy20.


It contains “proprietary, attenuated and killed non-pathogenic gram-negative bacteria that have demonstrated broad anti-tumor and anti-viral activity.”


In layman’s speak, Decoy20 is a weakened bacteria that INDP theorizes will broadly activate the immune system while passing quickly from the system without making the patient too sick.


Theoretical immune reaction from Decoy20. Source: Indaptus website.


To date — and it’s still in the very early stages — the Phase 1 trial has borne that out.


Just last Tuesday, the company released interim data from the first group of patients to receive Decoy20. According to a company press release:

The interim data . . . demonstrated that as of August 31, 2023, each of the first cohort participants experienced transient activation of biomarkers associated with innate and/or adaptive immune responses, and generally expected transient adverse events, both associated with predicted rapid clearance of Decoy20.


That last part is important because the idea is for Decoy20 to be in and out — to cause a sustained immune response but not a sustained bacterial infection.


This lends weight to what has until now just been theory. The company presented the data to the Society for Immunotherapy of Cancer just this past Saturday. You can read more about it here.


This was the first big news INDP had since September, and it was certainly a blockbuster capable of powering last week’s rally. 


If Decoy20 works the way the company thinks it will, it could be a game changer for a whole host of cancer treatments.


The potential is tremendous, and I’m not the only one who sees it…


Where Does INDP Go From Here?


One great indicator of the promise in these early-stage biotechs is what company insiders are up to.


This year, there have been no sales of stock by company insiders. That’s exactly what we look for. 


At the same time, on August 17, insider Glen R. Anderson — who was already a 10% owner in the company — loaded up on 103,352 more shares at an average price of $2.09 for a total spend of $216,388. 


That’s nothing to sneeze at for a company with a market cap of $20 million, and shows considerable insider confidence.


It looks like investment bank H.C. Wainwright is extremely bullish on INDP as well. They just reiterated their 12-month price target of $12.00 on Friday, following the positive Phase 1 trial news. 


If they are right, that would be an eye-popping 380% gain from the Friday close.


Wrapping Up


Companies like INDP are real gems in otherwise uncertain markets. Their stock prices aren’t as tethered to broader market forces as your S&P 500 bigwigs. 


The important thing is results: strong news about trial success can propel the stock much higher than any Fed pronouncement.


That’s why I think this is the one stock that deserves your eyes 👀 today…


Take a close look at the technical indicators I mentioned, study the broader chart, and review the company website.


The bottom line is to do your homework. I really like INDP, and I think it merits your attention, but your assessment and your risk tolerance may differ from mine.


I’ve been right on more of these “Bright Ideas 💡” than I can count, but I’ve been wrong on some too — usually due to timing.


I’ll touch base with any updates, but in the meantime, have a great trading week. It’s sure to be a wild one.


To Your Success,

Jeff Bishop


By the way… Text “RAGE” to 1-(888) 404-5747 to get all of my latest HOT STOCK ideas delivered right to your phone (make sure you put the 1 in!).


*This investment involves substantial risk. Please see full disclosure below, and detailed discussion of risks and atypical results.



*PAID ADVERTISEMENT. Raging Bull has currently been paid fifteen thousand dollars from Sica Media who was compensated by a third party not affiliated with the Company for advertising Indaptus Therapeutics, Inc. from a period beginning on November 6 through November 7, 2023. The third party, Company, or their affiliates may own and likely wish to liquidate shares of the Company at or near the time you receive this advertisement, which has the potential to hurt share prices. This advertisement and other marketing efforts, including alerts, may increase investor and market awareness, which may result in an increased number of shareholders owning and trading the securities of Indaptus Therapeutics, Inc., increased trading volume, and possibly an increased share price of Indaptus Therapeutics, Inc.’s securities, which may or may not be temporary and decrease once the marketing arrangement has ended. As a result of this advertisement and other marketing efforts, Raging Bull may receive advertising revenue from new advertisers and collect email addresses from readers that it may be able to monetize. As of the date of the issuance of this advertisement, the owners of Raging Bull do not hold a position in Indaptus Therapeutics, Inc., though they reserve the right to buy or sell shares in the covered company at any time following the dissemination of this communication.


FOR COMMERCIAL AND INFORMATIONAL PURPOSES ONLY; NOT INVESTMENT ADVICE. This advertisement is for commercial and informational purposes only. A portion of our business is engaged in the promotion, marketing, and advertising of companies including public companies. A portion of Raging Bull’s business model is to receive financial compensation to promote public companies, conduct investor relations advertising and marketing, and publicly disseminate information regarding public companies through our websites email, SMS, and push notifications among other methods of communication. This compensation is a major conflict of interest in our ability to provide unbiased reporting. Therefore, this communication should be viewed as a commercial advertisement only. Note, we periodically conduct interviews and issue stock alerts that we are not compensated for. These are purely for the purpose of company awareness, and to generate subscription revenues. We have not investigated the background of the hiring third party or parties. All material information contained in this advertisement is based on information generally available to the public, including information released to the public or filed by the Company with applicable regulators which public information is believed to be reliable and accurate. Nevertheless, Raging Bull cannot guarantee the accuracy or completeness of the information. This advertisement does not purport to be a complete analysis of any company’s financial position. This advertisement or any statements made in it is not, and should not be construed to be, personalized investment advice directed to or appropriate for any particular individual. The statements made in this advertisement should NOT be relied upon for purposes of investing in the companies mentioned in this advertisement, nor should they be construed as a personalized recommendation to you to buy, sell, or hold any position in any security mentioned in this advertisement or in any other security or strategy. It is strongly recommended that you consult a licensed or registered professional before making any investment decision.


SUBSTANTIAL RISK INVOLVED. Any individual who chooses to invest in any securities of the companies mentioned in this advertisement should do so with caution. Investing or transacting in any securities involves substantial risk; you may lose some, all, or possibly more than your original investment. Readers of this advertisement bear responsibility for their own investment research and decisions and should use information from this advertisement only as a starting point for doing additional independent research in order to allow individuals to form their own opinion regarding investments. It is easy to lose money investing or trading, and we recommend always seeking individual advice from a licensed or registered professional and educating yourself as much as possible before considering any investments.  Never invest in any stock featured in this advertisement, on our site or emails unless you can afford to lose your entire investment.



NOT AN INVESTMENT ADVISOR OR REGISTERED BROKER. Raging Bull, or any of their owners, employees or independent contractors is not currently registered as a securities broker-dealer, broker, investment advisor (IA), or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization.


USE OF FORWARD-LOOKING STATEMENTS. Our advertisements including this advertisement and related emails, reports and alerts may contain forward-looking statements, which are not guaranteed to materialize due to a variety of factors. We do not guarantee the timeliness, accuracy, or completeness of the information in this advertisement, related emails, reports or alerts or on our website or media webpage. This information is believed to be accurate and correct but has not been independently verified and is not guaranteed to be correct.  Certain statements made in this advertisement may constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and 21E of the Exchange Act of 1934. Forward-looking statements often include words such as “believes,” “anticipates,” “estimates,” “expects,” “projects,” “intends,” or other similar expressions of future performance or conduct. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made and are not statements of historical fact. They involve many risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. There is no guarantee that past performance will be indicative of future results. Raging Bull does not undertake an obligation to update forward-looking statements in light of new information or future events. Readers can and should review all public SEC filings made by the companies profiled in the Advertisements at https:// www .sec .gov/edgar/searchedgar/company search


TRADEMARKS. All trademarks used in this advertisement are the property of their respective trademark holders and no endorsement by such owners of the contents of the advertisement is made or implied.

WE MAY HOLD SECURITIES DISCUSSED. Ragingbull.com, LLC, its owners, and its employees may purchase, sell, or hold long or short positions in securities of the companies mentioned in this communication.